Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.36 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 7/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898995 | 0.84 | KIF11 (0.49) | KIF11SMN1; SMN2SLC26A6HPGDLMNA | |
| SCHEMBL3867068 | 0.82 | KIF11 (0.52) | KIF11MEN1KMT2AKIF23GHSR | |
| SCHEMBL4040410 | 0.75 | KIF11 (0.60) | KIF11SMN1; SMN2KIF23HPGD | |
| SCHEMBL5741124 | 0.74 | SMN1; SMN2 (0.42) | KIF11MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL4038230 | 0.71 | KIF11 (0.79) | KIF11 | |
| SCHEMBL4038069 | 0.71 | KIF11 (0.92) | KIF11 | |
| SCHEMBL4044184 | 0.71 | KIF11 (0.79) | KIF11 | |
| SCHEMBL5246052 | 0.70 | TLR7 (0.43) | KIF11SMN1; SMN2TSHR | |
| SCHEMBL4040565 | 0.70 | KIF11 (0.76) | KIF11 | |
| SCHEMBL4036221 | 0.70 | KIF11 (0.65) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | claimed |
| EP-1323716-B1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | TAKEDA PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7456162-B2 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7101867-B2 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-05 | — | — | US | disclosed |
| US-20050187238-A1 | Benzofuran derivatives, their production and use | OHKAWA SHIGENORI (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1136477-B1 | BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1323716-A1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6479536-B1 | Benzofuran derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
| US-20020160996-A1 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1136477-A1 | BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | NES, MKI67, CCNO | KIF11 3432/4885MEN1 2906/4885KMT2A 1061/4885 |
| US-20050187238-A1 | Benzofuran derivatives, their production and use | WDR1, WDR82, CBR1 | KIF11 4805/4885MEN1 2912/4885KMT2A 2211/4885 |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | NES, HAT1, PROX1 | KIF11 3886/4885MEN1 3718/4885KMT2A 451/4885 |
| US-20020160996-A1 | Benzofuran derivatives, their production and use | PARK7, WDR1, WHR1 | KIF11 4840/4885MEN1 3777/4885KMT2A 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.